Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
Open Access
- 20 September 2015
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 386 (10008), 2059-2068
- https://doi.org/10.1016/s0140-6736(15)00257-3
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitusJournal of Hypertension, 2013
- Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertensionNature Genetics, 2013
- 2013 ESH/ESC Guidelines for the management of arterial hypertensionBlood Pressure, 2013
- Resistant hypertensionBMJ, 2012
- Management of hypertension: summary of NICE guidanceBMJ, 2011
- Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT)Hypertension, 2011
- A comparative study on inter and intralaboratory reproducibility of renin measurement with a conventional enzymatic method and a new chemiluminescent assay of immunoreactive reninJournal of Hypertension, 2010
- Spironolactone use and renal toxicity: population based longitudinal analysisBMJ, 2010
- Effects of Dietary Sodium Reduction on Blood Pressure in Subjects With Resistant HypertensionHypertension, 2009
- Resistant Hypertension: Diagnosis, Evaluation, and TreatmentHypertension, 2008